Trial · NCT01511978
Adverse events52
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 52
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal discomfort | Gastrointestinal disorders | Continuous 3,4-Diaminopyridine (3,4-DAP) | 0 | 14 | |
| other | Abdominal discomfort | Gastrointestinal disorders | 3,4-DAP Taper to Placebo | 2 | 18 | |
| other | Respiratory tract infection | Infections and infestations | Continuous 3,4-Diaminopyridine (3,4-DAP) | 0 | 14 | |
| other | Respiratory tract infection | Infections and infestations | 3,4-DAP Taper to Placebo | 2 | 18 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Continuous 3,4-Diaminopyridine (3,4-DAP) | 1 | 14 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | 3,4-DAP Taper to Placebo | 1 | 18 | |
| other | Headache | Nervous system disorders | Continuous 3,4-Diaminopyridine (3,4-DAP) | 1 | 14 | |
| other | Headache | Nervous system disorders | 3,4-DAP Taper to Placebo | 1 | 18 | |
| other | Nasopharyngitis | Infections and infestations | Continuous 3,4-Diaminopyridine (3,4-DAP) | 1 | 14 | |
| other | Nasopharyngitis | Infections and infestations | 3,4-DAP Taper to Placebo | 1 | 18 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Continuous 3,4-Diaminopyridine (3,4-DAP) | 1 | 14 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | 3,4-DAP Taper to Placebo | 1 | 18 | |
| other | Abdominal pain lower | Gastrointestinal disorders | Continuous 3,4-Diaminopyridine (3,4-DAP) | 0 | 14 | |
| other | Abdominal pain lower | Gastrointestinal disorders | 3,4-DAP Taper to Placebo | 1 | 18 | |
| other | Blood glucose increased | Investigations | Continuous 3,4-Diaminopyridine (3,4-DAP) | 0 | 14 | |
| other | Blood glucose increased | Investigations | 3,4-DAP Taper to Placebo | 1 | 18 | |
| other | Cheilitis | Gastrointestinal disorders | Continuous 3,4-Diaminopyridine (3,4-DAP) | 0 | 14 | |
| other | Cheilitis | Gastrointestinal disorders | 3,4-DAP Taper to Placebo | 1 | 18 | |
| other | Dizziness | Nervous system disorders | Continuous 3,4-Diaminopyridine (3,4-DAP) | 0 | 14 | |
| other | Dizziness | Nervous system disorders | 3,4-DAP Taper to Placebo | 1 | 18 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01511978/events